ArriVent BioPharma Common Stock Statistics
Share Statistics
ArriVent BioPharma Common Stock has 33.70M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 33.70M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | 655 |
| FTD / Avg. Volume | 0.27% |
Short Selling Information
The latest short interest is 3.54M, so 10.53% of the outstanding shares have been sold short.
| Short Interest | 3.54M |
| Short % of Shares Out | 10.53% |
| Short % of Float | 18.24% |
| Short Ratio (days to cover) | 24.21 |
Valuation Ratios
The PE ratio is -9.22 and the forward PE ratio is -11.82.
| PE Ratio | -9.22 |
| Forward PE | -11.82 |
| PS Ratio | 0 |
| Forward PS | 162.9 |
| PB Ratio | 4.22 |
| P/FCF Ratio | -11.45 |
| PEG Ratio | n/a |
Enterprise Valuation
ArriVent BioPharma Inc. Common Stock has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 13.76, with a Debt / Equity ratio of 0.
| Current Ratio | 13.76 |
| Quick Ratio | 13.78 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.46% and return on capital (ROIC) is -49.2%.
| Return on Equity (ROE) | -0.46% |
| Return on Assets (ROA) | -0.43% |
| Return on Capital (ROIC) | -49.2% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.73M |
| Employee Count | 40 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 0, so ArriVent BioPharma Common Stock's price volatility has been lower than the market average.
| Beta | 0 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 29.42 |
| 200-Day Moving Average | 22.5 |
| Relative Strength Index (RSI) | 36.33 |
| Average Volume (20 Days) | 240.04K |
Income Statement
In the last 12 months, ArriVent BioPharma Common Stock had revenue of $0 and earned -$69.33M in profits. Earnings per share was $-2.17.
| Revenue | 0 |
| Gross Profit | 0 |
| Operating Income | -74.59M |
| Net Income | -69.33M |
| EBITDA | -74.59M |
| EBIT | - |
| Earnings Per Share (EPS) | -2.17 |
Balance Sheet
The company has $150.39M in cash and $317.00K in debt, giving a net cash position of $150.07M.
| Cash & Cash Equivalents | 150.39M |
| Total Debt | 317.00K |
| Net Cash | 150.07M |
| Retained Earnings | -157.84M |
| Total Assets | 163.10M |
| Working Capital | 148.34M |
Cash Flow
In the last 12 months, operating cash flow was -$55.84M and capital expenditures $0, giving a free cash flow of -$55.84M.
| Operating Cash Flow | -55.84M |
| Capital Expenditures | 0 |
| Free Cash Flow | -55.84M |
| FCF Per Share | -1.75 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
AVBP does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -8.16% |
| FCF Yield | -6.23% |
Analyst Forecast
The average price target for AVBP is $36, which is 35.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $36 |
| Price Target Difference | 35.4% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | -0.51 |
| Piotroski F-Score | 1 |